Company: CYTK
Filing Date: 2025-09-22
Form Type: 8-K
Source: 0001193125-25-209437
Chunk: 5

Company: CYTOKINETICS INC
Filing Date: 2025-09-22
Form: 8-K
Item: Item 1.01
Chunk 5
---
 issued upon conversion of the Notes will be issued in reliance upon Section 3(a)(9) of the Securities Act as involving an exchange by the Company exclusively with its security holders. Initially, a maximum of 15,072,300 shares of the Company’s common stock may be issued upon conversion of the Notes and based on the initial maximum conversion rate of 20.0964 shares of common stock per $1,000 principal amount of Notes, which is subject to customary anti-dilution adjustment provisions.

The 2,168,806 shares of the common stock being issued in connection with the Note Exchange Transactions are being issued in reliance on the exemption from the registration requirements provided by Section 4(a)(2) of the Securities Act.

Item 8.01. Other Events.

On September 16, 2025, the Company issued a press release announcing the launch of the offering of the Notes. On September 16, 2025, the Company issued a press release announcing the pricing of the offering of the Notes. Copies of the press releases are filed as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K andare incorporated by reference herein.

Forward-Looking Statements

This Current Report on Form8-Kincludes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the offering of the Notes, the potential effects of the Note Exchange Transactions and statements concerning the use of proceeds from the offering. Forward-looking statements represent the Company’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, the satisfaction of the closing conditions related to the offering and risks relating to the Company’s business, including in its Annual Report on Form10-Kfor the period ended December 31, 2024, filed with the SEC on February 27, 2025 and Quarterly Reports on Form10-Qfor the periods ended March 31, 2025 and June 30, 2025, filed with the SEC on May 6, 2025 and August 7, 2025, respectively, and the future quarterly and current reports that the Company files with the SEC. The forward-looking statements included in this Current Report on Form8-Kspeak only as of the date of this Current Report on Form8-K